KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Intangibles (2016 - 2025)

Teva Pharmaceutical Industries' Intangibles history spans 17 years, with the latest figure at $3.8 billion for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles fell 14.42% year-over-year to $3.8 billion, compared with a TTM value of $3.8 billion through Dec 2025, down 14.42%, and an annual FY2025 reading of $3.8 billion, down 14.42% over the prior year.
  • Intangibles for Q4 2025 was $3.8 billion at Teva Pharmaceutical Industries, down from $3.9 billion in the prior quarter.
  • The five-year high for Intangibles was $8.4 billion in Q1 2021, with the low at $3.8 billion in Q4 2025.
  • Average Intangibles over 5 years is $5.8 billion, with a median of $5.6 billion recorded in 2023.
  • Year-over-year, Intangibles fell 18.37% in 2022 and then fell 13.58% in 2023.
  • Tracing TEVA's Intangibles over 5 years: stood at $7.5 billion in 2021, then dropped by 16.02% to $6.3 billion in 2022, then decreased by 14.08% to $5.4 billion in 2023, then dropped by 17.99% to $4.4 billion in 2024, then dropped by 14.42% to $3.8 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Intangibles are $3.8 billion (Q4 2025), $3.9 billion (Q3 2025), and $4.1 billion (Q2 2025).